WebFollowing its earnings release, 28 days ago, IONS stock has drifted -4.1% lower. From the time it announced earnings, IONS traded in a range between 32.69 and 36.86. The last … Web23 feb. 2024 · Ionis Pharmaceuticals IONS reported a loss of 37 cents per share for fourth-quarter 2024, much narrower than the Zacks Consensus Estimate of a loss of $1.06 and …
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue …
WebIonis-STM, école de double compétence Master of Business Administration (MBA) ... I earned my PhD in Neuroscience in 2009 through a private/public partnership between the Pierre Fabre Research Institute and the Psychiatry and Neuroscience Center of Paris. ... Scientific Reports 2015 Voir la publication. Alcool, ... Web12 apr. 2024 · StockNews.com started coverage on shares of Ionis Pharmaceuticals in a report on Thursday, ... The stock has a market cap of $5.32 billion, a price-to-earnings ratio of -19.59 and a beta of 0.54. data centers across the world
Ionis reports third quarter 2024 financial results and recent …
Web11 apr. 2024 · Ionis Pharmaceuticals had a negative net margin of 45.75% and a negative return on equity of 43.01%. The business’s revenue was down 65.5% compared to the same quarter last year. During the same period last year, the … Web22 feb. 2024 · As of December 31, 2024, Ionis had cash, cash equivalents and short-term investments of $2.0 billion compared to $2.1 billion at December 31, 2024. Ionis' year-end cash balance does not include... Web22 feb. 2024 · Ionis reports fourth quarter and full year 2024 financial results. Eplontersen NDA submitted to FDA; tofersen under regulatory review for marketing approval in U.S. and EU. Phase 3 data planned for eplontersen and olezarsen; robust late-stage … bitlocker recovery screen bypass